A business in context

LXEO research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-09-29 · 0001193125-26-407555 · Items 2.01,3.02,9.01

  2. 4 · Ownership change

    Report date 2026-09-24 · 0002109299-26-000009

  3. 4 · Ownership change

    Report date 2026-09-24 · 0002083206-26-000009

  4. 4 · Ownership change

    Report date 2026-09-24 · 0002024096-26-000015

  5. 4 · Ownership change

    Report date 2026-09-24 · 0001995218-26-000017

  6. 8-K · Current report

    Report date 2026-09-16 · 0001193125-26-397221 · Items 1.01,8.01,9.01

  7. 4 · Ownership change

    Report date 2026-08-18 · 0002083206-26-000007

  8. 4 · Ownership change

    Report date 2026-08-18 · 0002024096-26-000013

  9. 4 · Ownership change

    Report date 2026-08-18 · 0001995218-26-000015

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-345724

  11. 8-K · Current report

    Report date 2026-08-12 · 0001193125-26-345722 · Items 2.02,8.01,9.01

  12. 4 · Ownership change

    Report date 2026-06-29 · 0002109299-26-000007

  13. 8-K · Current report

    Report date 2026-06-25 · 0001193125-26-288703 · Items 5.07

  14. 8-K · Current report

    Report date 2026-06-15 · 0001193125-26-270275 · Items 7.01,8.01,9.01

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-215678

  16. 8-K · Current report

    Report date 2026-05-11 · 0001193125-26-215674 · Items 2.02,8.01,9.01

  17. DEF 14A · Proxy statement

    Report date 2025-12-31 · 0001193125-26-193930

  18. 8-K · Current report

    Report date 2026-04-28 · 0001193125-26-193927 · Items 5.02

  19. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-132085

  20. 8-K · Current report

    Report date 2026-03-30 · 0001193125-26-131792 · Items 2.02,8.01,9.01

  21. 8-K · Current report

    Report date 2026-01-30 · 0001193125-26-039425 · Items 5.02

  22. 8-K · Current report

    Report date 2026-01-27 · 0001193125-26-023339 · Items 5.02

  23. 8-K · Current report

    Report date 2026-01-12 · 0001193125-26-010091 · Items 7.01,8.01,9.01

  24. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-265757

  25. 8-K · Current report

    Report date 2025-11-05 · 0001193125-25-265755 · Items 2.02,9.01

  26. 8-K · Current report

    Report date 2025-10-16 · 0001193125-25-242652 · Items 1.01,2.02,3.02,8.01,9.01

  27. 8-K · Current report

    Report date 2025-10-07 · 0001193125-25-232514 · Items 7.01,8.01,9.01

  28. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-108427

  29. 8-K · Current report

    Report date 2025-08-14 · 0000950170-25-108426 · Items 2.02,5.02,9.01

  30. 8-K · Current report

    Report date 2025-06-30 · 0000950170-25-091671 · Items 5.07

  31. 8-K · Current report

    Report date 2025-05-27 · 0000950170-25-077377 · Items 1.01,3.02,7.01,9.01

  32. 10-Q/A · Quarterly report

    Report date 2025-03-31 · 0000950170-25-071709

  33. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-068536

  34. 8-K · Current report

    Report date 2025-05-12 · 0000950170-25-068534 · Items 2.02,9.01

  35. DEF 14A · Proxy statement

    Report date 2024-12-31 · 0000950170-25-059375

  36. 8-K · Current report

    Report date 2025-04-07 · 0000950170-25-051345 · Items 7.01,8.01,9.01

  37. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-043486

  38. 8-K · Current report

    Report date 2025-03-24 · 0000950170-25-043485 · Items 2.02,9.01

  39. 8-K · Current report

    Report date 2025-01-13 · 0000950170-25-004566 · Items 8.01

  40. 8-K · Current report

    Report date 2024-12-18 · 0000950170-24-138224 · Items 5.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 7 transaction rows7SGrant / award: 11 transaction rows11AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

18 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-24
2026-09-28
Bhalla Narinder PalA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
54750.00.0
2026-09-24
2026-09-28
Tamayo Louis EdwardA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
54750.00.0
2026-09-24
2026-09-28
Otero Jose ManuelA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
54750.00.0
2026-09-24
2026-09-28
Townsend Richard NolanA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
145500.00.0
2026-09-14
2026-09-28
Bhalla Narinder PalA · Grant / award
Acquired
Common Stock2714.03.58
2026-09-14
2026-09-28
Otero Jose ManuelA · Grant / award
Acquired
Common Stock2110.02.64
2026-09-14
2026-09-28
Townsend Richard NolanA · Grant / award
Acquired
Common Stock2306.02.64
2026-08-18
2026-08-19
Tamayo Louis EdwardS · Sale
Disposed
Common Stock4117.04.91
2026-08-18
2026-08-19
Otero Jose ManuelS · Sale
Disposed
Common Stock1304.04.96
2026-08-18
2026-08-19
Townsend Richard NolanS · Sale
Disposed
Common Stock3345.04.95
2026-07-01
2026-07-01
Bhalla Narinder PalS · Sale
Disposed
Common Stock22306.04.42
2026-07-01
2026-07-01
Tamayo Louis EdwardS · Sale
Disposed
Common Stock4641.04.49
2026-07-01
2026-07-01
Otero Jose ManuelS · Sale
Disposed
Common Stock4666.04.48
2026-07-01
2026-07-01
Townsend Richard NolanS · Sale
Disposed
Common Stock25947.04.48
2026-06-29
2026-07-01
Bhalla Narinder PalA · Grant / award
Acquired
Common Stock55000.00.0
2026-06-29
2026-07-01
Tamayo Louis EdwardA · Grant / award
Acquired
Common Stock12000.00.0
2026-06-29
2026-07-01
Otero Jose ManuelA · Grant / award
Acquired
Common Stock12060.00.0
2026-06-29
2026-07-01
Townsend Richard NolanA · Grant / award
Acquired
Common Stock67000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001907108Lexeo Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    Year endedReported USD revenueCPI-adjusted USD revenue
    2022-12-31$654.0K$752.8K

    Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

    Explore the CPI history ↗